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1. Introduction 
In the 1950s, the monoamines 5-hydroxytryptamine (5-HT) (Woolley & Shaw, 1954), 
noradrenaline (NA) (Vogt, 1954), and dopamine (DA) (Carlsson, 1958) were identified in the 
brain. After this discovery, it was identified that the tricyclic compound imipramine and the 
antituberculosis drug iproniazid were effective in the treatment of clinical depression, and 
that these drugs can increase the extracellular concentration of monoamines by inhibiting 
the re-uptake of 5-HT and NA and by blocking monoamine oxidase (MAO) respectively. 
These findings have led to the catecholamine hypothesis of depression (Schildkraut, 1965), 
followed by the monoamine hypothesis (Coppen, 1967), which propose that depression is 
caused by deficiencies within the central catecholaminergic or monoaminergic systems 
respectively. At present, it is understood that all antidepressants increase monoamine levels 
in the brain. Other evidence supporting the monoamine hypothesis has also been put 
forward: reserpine, which depletes monoamines in the synaptic cleft, caused depressive 
symptoms in some patients taking it for the treatment of hypertension. 5-HIAA, the primary 
metabolite of 5-HT, was seen as reduced in the cerebrospinal fluid of clinically depressed 
patients. All these findings suggest that monoamine concentrations in the brain are reduced 
in depressive patients. 
Despite compelling evidence supporting the monoamine hypothesis, there is an enigma 
which must be resolved. Although antidepressants raise monoamine concentrations 
immediately after their administration, it takes several weeks or more for their clinical 
efficacy to become apparent. The delayed onset of action of antidepressants suggests that 
they induce slowly occurring changes in the monoaminergic systems, rather than simply 
increasing the monoamine concentrations. It has been reported that chronic (but not 
acute) treatments with antidepressants cause the down-regulation of postsynaptic ǃ-
adrenergic receptors (Banerjee et al., 1977; Vetulani & Sulser, 1975). This finding 
presumably explained the delayed onset of antidepressant action. However, the down-
regulation of ǃ-adrenergic receptors appeared to contradict the monoamine hypothesis of 
depression, which proposes hypofunction in the monoaminergic systems during 
depression. The decreased ǃ-adrenergic receptor sensitivity observed following 
treatments suggests that antidepressants exert clinical effects by attenuating hyperfunction 
of the noradrenergic system. 
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Fig. 1. A link between postsynaptic receptors (ǃ-receptors) and presynaptic axons (NA 
axons). The degeneration of presynaptic NA axons induced by an NA-specific neurotoxin 
causes supersensitivity of postsynaptic ǃ-receptors, while repeated administration of 
noradrenergic antidepressants causes subsensitivity. Based on these findings, the 
antidepressants have been shown to have the ability to induce NA axon regeneration 
(Nakamura, 1990,1991). This has led to the view that the degeneration of NA axons is 
involved in the pathophysiology of depression. 
This discrepancy is resolved by considering an association of the receptor sensitivity with 
morphological changes (Fig. 1). Denervated skeletal muscle becomes supersensitive to 
acetylcholine due to an increase in the number of acetylcholine receptors on the muscle 
membrane (denervation supersensitivity). Denervation supersensitivity similar to this 
occurs in the central noradrenergic system: denervation of cortical NA axons with 6-
hydroxydopamine (6-OHDA), a neurotoxin to catecholaminergic neurons, causes 
supersensitivity (up-regulation) in cortical ǃ-adrenergic receptors (Sporn et al., 1976). As up-
regulation of ǃ-adrenergic receptors is associated with denervation of NA axons, it is 
possible that the converse is also true: down-regulation of ǃ-adrenergic receptors results 
from an increase in the density of NA axons, i.e., regeneration or sprouting of NA axons. 
This idea has led to the monoamine axon hypothesis of depression, which proposes the 
involvement of degeneration or retraction of monoaminergic axons in the pathophysiology 
of depression (Nakamura, 1990: Harley, 2003). According to the monoamine axon 
hypothesis, antidepressant drugs exert their effects by inducing regeneration or sprouting of 
monoaminergic axons. 
This review focuses on the effects of antidepressants on the morphological plasticity of 
monoaminergic axons (mainly 5-HT- and NA-axons) in the adult and developing brain. 
There is no report showing a link between morphological plasticity and antidepressants in 
DA axons, although DA neurons have been reported as having the ability to induce axonal 
sprouting (Hansen et al., 1995; Blanchard et al., 1996; Finkelstein et al., 2000; Stanic et al., 
www.intechopen.com
 
Antidepressants and Morphological Plasticity of Monoamine Neurons 
 
75 
2003). Therefore, this review is limited to links between antidepressants and the 
morphological plasticity of 5-HT and NA neurons. In addition, other factors including 
stress, retinoic acid, and interferon-ǂ that affect morphological plasticity of monoamine 
neurons are described in relation to clinical depression. This review also discusses slow-
acting (monoamininergic) and fast-acting (glutamatergic) antidepressants in relation to a 
possible link between the monoaminergic and glutamatergic systems. 
2. Effects of antidepressants on the density of monoaminergic axons 
There is evidence to support the monoamine axon hypothesis of depression. It has been 
shown that antidepressants that increase extracellular NA concentrations also enhance the 
regeneration of damaged NA axons (Nakamura, 1990, 1991), and that antidepressants that 
modulate 5-HT release from 5-HT axon terminals also induce axonal sprouting of 5-HT 
neurons (Zhou et al., 2006). Focusing on the noradrenergic system, we developed a rat 
model by which we can assess the ability of antidepressant drugs to induce the regeneration 
of NA axons (Nakamura, 1990, 1991, 1994). First, to denervate NA axons locally, 6-OHDA (2 
㎍/0.5 ㎕) was injected bilaterally in the frontal cortex. 6-OHDA was delivered from the tip 
of a 30-gauge metallic cannula, which was connected to an infusion pump with 
polyethylene tubing. Two weeks after the toxin infusion, one hemisphere was infused with 
an antidepressant at the same cortical site, and the other was infused with saline. These 
drugs were delivered continuously from the tip of an infusion cannula connected to osmotic 
minipumps (Alzet, model 2002) for more than two weeks (Kasamatsu et al., 1979). To 
visualize NA axons, we used either fluorescence histochemistry or immunohistochemistry. 
The size of NA (and DA) axon denervation was then compared between the antidepressant- 
and saline-infused hemispheres. We showed that antidepressants that increase the 
extracellular concentration of NA, such as desipramine, maprotiline, and mianserin, have 
the ability to induce regeneration of NA axons, but fluoxetine, a potent reuptake inhibitor of 
5-HT, does not (Nakamura, 1990, 1991). Desipramine and maprotiline are potent reuptake 
inhibitors of NA, while mianserin has little or no effect on NA reuptake inhibition but 
enhances NA release by blocking presynaptic ǂ2-adrenergic receptors. Zhou et al. (2006) 
have demonstrated the ability of antidepressants to induce axonal sprouting of 5-HT 
neurons by systemic injections of antidepressants in rats without damaging the 5-HT axons. 
In this study, they tested three types of antidepressants: the 5-HT reuptake inhibitor 
fluoxetine, the 5-HT reuptake enhancer tianeptine, and the NA reuptake inhibitor 
desipramine. These antidepressant drugs were administered intraperitoneally for four 
weeks. The density of 5-HT axons was examined by visualizing 5-HT axons using antibody 
immunohistochemistry on 5-HT or 5-HT transporters. They found that fluoxetine and 
tianeptine, but not desipramine, increased the density of 5-HT axons in the cerebral cortex 
and some limbic forebrain areas. Using an anterograde labeling technique, they also showed 
that branching increased in terminal axons from the dorsal raphe. These findings all 
strongly indicate that antidepressants that modulate 5-HT reuptake also induce axonal 
sprouting of 5-HT neurons. 
These findings appear to suggest that an increased extracellular NA concentration in the 
synaptic cleft is required to induce axonal regeneration in NA neurons. Regarding 5-HT 
neurons, however, it is unlikely that an increase in extracellular 5-HT concentration causes 
axonal sprouting of 5-HT neurons, because the antidepressant-induced sprouting of 5-HT 
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axons occurs after treatments with both 5-HT reuptake inhibitors and facilitators (Zhou et 
al., 2006). It is worth noting that axonal regeneration in NA neurons is induced by NA 
antidepressants but not by 5-HT antidepressants (fluoxetine), while 5-HT but not NA 
antidepressants are able to induce axonal sprouting in 5-HT neurons. This finding suggests 
the possibility that terminal axons of the monoamine neurons form, at least in part, in 
relation to changes in the release of their own neurotransmitter. 
3. Effects of stress on the morphology of monoaminergic axons 
Many studies have demonstrated that 5-HT and NA axons have a great capacity to 
regenerate in response to brain damage (Nygren et al., 1971; Bjorklund et al., 1973; Nygren 
et al., 1974; Bjorklund & Lindvall, 1979; Wiklund & Bjorklund, 1980; Fritschy & Grzanna, 
1992; Liu et al., 2003). It has been noted that the regeneration of 5-HT axons occurred as 
early as 28 days after damage from 5-HT neurotoxin injection, while the regeneration of NA 
axons was not evident 60 days after NA neurotoxin injection (Liu et al., 2003). Furthermore, 
repeated stress, which is a major cause of depression, has been shown to cause degeneration 
(or retraction) or regeneration (or sprouting) of monoaminergic axons (Nakamura et al., 
1989; Sakaguchi & Nakamura, 1990; Kitayama et al., 1994, 1997; Liu et al., 2004, 2006; 
Kuramochi et al., 2009). Of interest is that the effects of repeated stress on the morphology of 
5-HT and NA axons are not the same. For example, in cortices partially denervated by either 
5-HT or NA neurotoxin, repeated stress causes 5-HT axon sprouting and NA axon retraction 
in cortical regions outside the denervation site (Liu et al., 2004). Moreover, the expression of 
brain-derived neurotrophic factor (BDNF), reportedly a neurotrophic factor for 5-HT axons 
(Eaton et al., 1995; Mamounas et al., 1995, 2000), was found to increase in cortical regions 
where 5-HT axon sprouting had occurred in response to stress. These findings suggest that 
the molecular mechanism of axonal regeneration or sprouting is different between 5-HT and 
NA axons. As mentioned earlier, this possibility is also supported by the finding that 
sprouting of 5-HT and regeneration of NA axons are induced by 5-HT and NA 
antidepressants, respectively. 
4. Link between morphology of monoaminergic axons and depressive 
behavior 
There are reports showing a link between morphological changes in monoaminergic axons 
and depressive symptoms in animal models of depression. Kitayama et al. (1994, 1997) have 
demonstrated that an animal model of depression resulted in the degeneration of cortical 
NA axon terminals. Model animals were subjected to long-term walking stress for two 
weeks, and showed depressive behaviors including prolonged inactivity, seclusion, 
aggression, motor retardation, lack of coupling behavior, fitful sleep, weight loss, and 
hypersensitivity to light and sound (Hatotani et al., 1977, 1979; Kitayama et al., 1994, 1997). 
In this model, the density of NA axons in the frontal cortex projecting from the locus 
coeruleus (LC) was examined using retrograde labeling of LC neurons with horseradish 
peroxidase injected into the cortex and immunohistochemical staining of cortical axons with 
dopamine-ǃ-hydroxylase antibody. The NA axon density was significantly reduced in the 
depressed rats, and when subjects were allowed to engage in spontaneous running activity, 
their recovery rates were positively correlated with the density of NA axons (Kitayama et 
al., 1997). The density of cortical NA axons in depressed rats was restored by chronic 
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treatment with imipramine (Kitayama et al., 1994, 1997) producing a reversal of depressive 
behaviors (Kitayama et al., 1987). These findings all support the possibility that 
degeneration of NA axons is involved in the pathophysiology of depression, and that 
antidepressants exert their clinical efficacy by inducing the regeneration of NA axons. It is 
notable that some of the animals subjected to long-term forced walking stress did not 
demonstrate persistent inactivity but gradually recovered to control levels after the end of 
the stress treatments (spontaneous recovery rats). The spontaneous recovery rats showed an 
increase, rather than a decrease, in the density of NA axons as compared to unstressed 
control rats (Kitayama et al., 1997). This finding suggests that adaptation to stress produces 
regeneration or sprouting of NA axons. This is consistent with the observation that 
sprouting of NA axons occurs following chronic mild stress (Nakamura et al., 1989; 
Sakaguchi & Nakamura, 1990; Nakamura, 1991). It remains to be determined whether 
morphological plasticity of 5-HT axons is involved in the depression model of long-term 
forced walking stress. 
A recent study has presented a possible link between the density of 5-HT axons and 
depressive behavior in rats (Kuramochi & Nakamura, 2009). This study examined the effects 
of postweaning social isolation stress on the density of 5-HT and NA axons and the presence 
of depressive behavior as assessed by immobility in the forced swim test. Social isolation 
rearing, which started at postnatal day (PD) 28 and continued until eight to nine weeks later, 
reduced the density of 5-HT but not NA axons in the central nucleus and basolateral nucleus 
of the amygdala and CA3 of the hippocampus. Moreover, increased immobility was 
observed in the forced swim test, suggesting that postweaning social isolation is a possible 
model of depression containing 5-HT axon deficits. In addition to postweaning social 
isolation rearing, this study examined the effects of postnatal treatment with the 
antidepressant clomipramine on the density of 5-HT and NA axons and the presence of 
depressive behavior. Paradoxically, it has been reported that neonatal treatment with 
clomipramine induced a rat model of depression as measured by increased immobility in 
the forced swim test (Velazquez-Moctezuma & Diaz Ruiz, 1992; Bonilla-Jaime et al., 2003). 
Furthermore, Vijayakumar and Meti (1999) have reported that neonatal treatment with 
clomipramine caused a decrease in levels of 5-HT and NA in several brain regions, 
including the frontal cortex and hippocampus. However, following the same treatment 
protocols, Kuramochi and Nakamura failed to find any changes in either the density of 5-HT 
and NA axons or the immobility observed in the forced swim test following neonatal 
treatment with clomipramine. This result is consistent with the finding that neonatal 
clomipramine treatment had little effect on tryptophan hydroxylase in the dorsal raphe or 5-
HT transporter expression in the cerebral cortex (Maciag et al., 2006), and no effect on forced 
swim immobility (Yoo et al., 2000). The contradictory results may be due to differences in rat 
strains used for each experiment. The experiments in which neonatal clomipramine induced 
depression used Wistar rats, whereas the experiments that failed to induce depression used 
Sprague-Dawley rats or Long-Evans rats. Therefore, it is possible that the Wistar strain is 
more susceptible to neonatal treatment with clomipramine than other strains (Kuramochi & 
Nakamura, 2009). 
Gonzalez and Aston-Jones (2006, 2008) have reported that light deprivation or long-term 
exposure to constant darkness in rats (DD) increased apoptosis in LC neurons and 
decreased the number of NA boutons in the cerebral cortex. The DD rats also demonstrated 
increased immobility in the forced swim test. The results suggest that the DD rats displaying 
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depressive behaviors could be an appropriate model for seasonal affective disorders (SAD) 
associated with limited light exposure, and that the pathophysiology of SAD may also 
involve degeneration or retraction of NA axons. Regarding the molecular mechanism of 
DD-induced depressive behaviors, Monje et al. (2011) have reported that activation of the 
proinflammatory cytokine interleukin-6 (IL-6) through the NF-κB signaling pathway plays a 
pivotal role in causing such behaviors, although it remains unclear whether elevated IL-6 
levels are associated with the DD-induced degeneration or retraction of NA axons. 
It remains to be determined that the major symptoms of depression, i.e., depressed mood 
and anhedonia, are induced by changes in the morphology of 5-HT and/or NA axons. It is 
likely that the degeneration of 5-HT and/or NA axons causes depressed mood rather than 
anhedonia, because anhedonia is thought to be associated with dysfunction of the 
dopaminergic reward system.   
5. Effects of chemical factors on morphology of monoaminergic axons 
To understand the molecular mechanisms of the morphological alterations of 
monoaminergic axons observed in depression models or induced by antidepressants, it is 
important to identify the endogenous chemical factors that affect these observed changes. 
The following are chemicals which have been reported to induce morphological changes 
of monoaminergic neurons (or axons) in relation to depressive behaviors (Interferon-ǂ, 
retinoic acids) or effects of antidepressants (phospholipase A2). However, it remains 
unclear what roles these chemicals play in the molecular mechanisms of stress-related 
depression.  
5.1 Interferon-α 
Interferon-ǂ (IFN-ǂ), a proinflammatory cytokine widely used for the treatment of cancers 
and viral illnesses, is well-known to induce depressive symptoms in 30-50% of patients 
(Schiepers et al., 2005; Raison et al., 2006). Based on this fact, Ishikawa et al. (2007) have 
shown that chronic treatments with IFN-ǂ in rats caused significant decreases in the 
densities of NA axons in the dorsal medial prefrontal cortex, ventral medial prefrontal 
cortex, and dentate gyrus of the hippocampus and of 5-HT axons in the ventral medial 
prefrontal cortex and amygdala. The changes in the density of NA axons became apparent 
after treatments with IFN-ǂ after nine weeks, but not at four weeks. It is not clear why such 
a long-term administration of IFN-ǂ was necessary to cause the degeneration of the 
monoaminergic axons. One possibility is that since IFN-ǂ has little ability to cross the blood-
brain barrier (BBB) (Collins et al., 1985; Wiranowska et al., 1989), long-term administration 
of IFN-ǂ may disrupt the BBB so that IFN-ǂ becomes able to enter the brain. Moreover, it is 
possible that the changes in the densities of the monoaminergic axons induced by chronic 
administration of IFN-ǂ are not due to IFN-ǂ directly. As IFN-ǂ increases other cytokines 
such as IL-6 and IL-8, which are also associated with depression (Bonaccorso et al., 2001), the 
cytokines induced by IFN-ǂ might be responsible for the observed changes in densities 
(Ishikawa et al., 2007). Taken together with a possible involvement of IL-6 in DD-induced 
depressive behavior (Monje et al., 2011), proinflammatory cytokines may play a critical role 
in the pathophysiology of depression because of their association with the degeneration or 
retraction of monoaminergic axons. 
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5.2 Phospholipase A2 
As mentioned in the Introduction, down-regulation of ǃ-adrenergic receptors induced by 
chronic administration of antidepressants may be associated with the antidepressant-
induced regeneration of NA axons. It has been reported that  down-regulation of ǃ-
adrenergic receptors following repeated application of ǃ-adrenergic agonists or chronic 
stress treatment is blocked by phospholipase A2 (PLA2) inhibitors, while this down-
regulation can be induced by the activation of PLA2 (Limbird & Lefkowitz, 1976; Mallorga 
et al., 1980; Hirata & Axelrod, 1980; Torda et al., 1981; Cohen et al., 1985). Manji et al. (1991) 
demonstrated that PLA2 activation is involved in the down-regulation of ǃ-adrenergic 
receptors induced by chronic desipramine treatment. Moreover, they suggested that in 
addition to elevated intrasynaptic levels of NA, desipramine acts directly on the 
postsynaptic membrane to contribute to the down-regulation. A possible link between 
down-regulation of ǃ-adrenergic receptors and the regeneration of NA axons raised the 
possibility that PLA2 is involved in the molecular mechanisms of the antidepressant-
induced regeneration of NA axons. Nakamura (1993, 1994) demonstrated that mepacrine or 
4-bromphenacyl bromide, which are PLA2 inhibitors, attenuates the regeneration of NA 
axons induced by desipramine, while the PLA2 activator mellitin induces NA axon 
regeneration. These findings support the notion that the antidepressant-induced 
regeneration of NA axons is mediated, at least in part, through PLA2.  
PLA2 is an enzyme that generates free fatty acids, such as arachidonic acid (AA), 
eicosapentenoic acid (EPA) and docosahexaenoic acid (DHA), by acting on membrane 
phospholipids. AA produces a variety of bioactive substances, such as prostaglandins and 
leukotrienes, via cycloxygenase or lipoxygenase. Since aspirin, a cycloxygenase inhibitor, 
had no apparent effect on the desipramine-induced regeneration of NA axons (unpublished 
data, Nakamura), it seems unlikely that the cycloxygenase system would play a critical role 
in the desipramine-induced regeneration of NA axons. Many reports have shown lower 
levels of EPA and/or DHA being associated with clinical depression (Peet et al., 1998; De 
Vriese et al., 2003; Frasure-Smith et al., 2004; McNamara et al., 2007; Lin et al., 2010; Su et al., 
2010). Animal studies demonstrated that administration of EPA and DHA had an 
antidepressant-like effect, reducing immobility in the forced swim test (Carlezon et al., 2005; 
Huang et al., 2008). Moreover, a recent study reported that the action of maprotiline, an NA 
reuptake inhibitor with the same effect, is mediated by EPA or DHA released by activation 
of calcium-independent PLA2 in the prefrontal cortex (Lee et al., 2011), although it remains 
unclear whether the EPA or DHA releases are associated with regeneration or sprouting of 
NA axons. Notably, there is one report which has shown the association between PLA2 
genes and the risk of IFN-ǂ-induced depression (Su et al., 2010). All these findings suggest 
that the PLA2-AA/EPA/DHA signaling pathway plays a crucial role in the occurrence of 
depressive symptoms, possibly by affecting the morphology of monoaminergic axons. 
5.3 Retinoic acids 
It has been reported that the acne drug Accutane (isotretinoin), the active component of 
which is 13-cis-retinoic acid (13-cis-RA), occasionally induces severe depression with 
suicidal ideation (Wysowski et al., 2001; Hull & D’Arcy, 2003; O’Donnell, 2003). There are 
conflicting studies to this effect: O’Reilly et al. (2006) demonstrated that chronic 
administration of 13-cis-RA increased depression-related behavior in adult mice, although 
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Ferguson et al. (2005) reported that 13-cis-RA or all-trans-RA had no such effect in rats. 
Based on findings that 13-cis-RA reduced neurogenesis and cell survival in the hippocampi 
of adult mice (Crandall et al., 2004 Sakai et al., 2004), McCaffery and coworkers have 
suggested that hippocampal cell loss is a major contributor to the pathophysiology of 
depression associated with 13-cis-RA use. Regarding the relationship between 13-cis-RA 
and the morphology of monoamine neurons, Ishikawa et al. (2008) demonstrated that the 
negative effects on the dendritic morphology of slice-cultured 5-HT neurons created by high 
doses of 13-cis-RA is mediated via retinoic acid receptor (RAR) and retinoid X receptor 
(RXR), which are nuclear receptors acting as ligand-inducible transcription factors 
(Chambon, 1996). It remains unclear whether 13-cis-RA induces the degeneration/retraction 
of monoaminergic axons through RAR and/or through RXR in the adult animal brain. It is 
notable that RA stimulates PLA2 activation via RA receptors, suggesting that the 
morphological effects of RAs such as 13-cis-RA are mediated along the PLA2 signaling 
pathway (Farooqui et al., 2004). 
5.4 1-Bromopropane 
1-Bromopropane (1-BP), a commonly used solvent in the dry cleaning industry (CDC, 2008; 
Blando et al., 2010), is used as an alternative to ozone layer depleting solvents as a cleaning 
agent for metal parts in electronics factories (Ichihara, 2005). Exposure to 1-BP has been 
reported to cause various neurological and neurobehavioral symptoms in humans, 
including numbness in the legs, ataxic gait and memory disturbances (Ichihara, 2005). In 
addition, workers exposed to 1-BP often display depressive symptoms (Ichihara et al., 2002; 
Majersik et al., 2007). To see if exposure to 1-BP causes degeneration of monoaminergic 
axons, Mohideen et al. (2011) examined the effects of repeated exposure to 1-BP on the 
density of 5-HT and NA axons in the rat brain. Exposure to 1-BP induced dose-dependent 
reductions in the density of NA axons in the prefrontal cortex and the basolateral nucleus of 
the amygdala, but no apparent change in the density of 5-HT axons. The results suggest that 
depressive symptoms in workers exposed to 1-BP may be associated with degeneration of 
NA axons in the brain, although the link between 1-BP and endogenous chemical factors 
involved in the degeneration of NA axons is unclear. The findings also suggest that there are 
exogenous chemical agents, as well as exogenous stressors, which can induce depressive 
symptoms, possibly by negatively affecting the morphology of monoaminergic axons. 
6. Slow-acting and fast-acting antidepressants 
In contrast to the delayed onset of the clinical efficacy of classical antidepressants, recent 
studies have reported that ketamine, an NMDA antagonist, exerts rapid antidepressant 
effects in humans (Berman et al., 2000; Zarate et al., 2006; Price et al., 2009). In animals, other 
NMDA antagonists such as MK-801 and CPP as well as ketamine have been reported to 
cause rapid antidepressant action in animals, though the effects are short-lasting compared 
to ketamine (Maeng et al., 2008; Autry et al., 2011). Many studies have corroborated the fact 
that the antidepressant effects of a single injection of ketamine persist up to 1-2 weeks in 
humans (Berman et al., 2000; Zarate et al., 2006; Price et al., 2009; Phelps et al., 2009; aan het 
Rot et al., 2010) and animals (Maeng et a., 2008; Li et al., 2010; Autry et al., 2011), while other 
studies failed to confirm the persistent effects of such an injection in rodents (Popik et al., 
2008; Lindholm et al., 2011). Since the fast-acting, sustained antidepressant effects of  
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Fig. 2A. All behaviors, including cognition and emotion, are processed by neural circuits 
mediated by the neurotransmitters glutamate and GABA. The operations of these functional 
neural circuits are modified by the modulatory systems, which exert their effects by 
releasing monoamines. 
 
Fig. 2B. In depression, the degeneration of monoaminergic axons containing 5-HT and/or 
NA may occur, resulting in the disorder of neural circuits that process behaviors such as 
emotion. 
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Fig. 2C. Slow-acting antidepressants affecting monoamine activity may exert their effects by 
inducing the regeneration of monoaminergic axons containing 5-HT and/or NA, thereby 
taking a few weeks or more to restore the normal conditions and operations of functional 
neural circuits. 
 
Fig. 2D. Fast-acting antidepressants may restore the normal conditions of functional neural 
circuits by directly affecting the glutamatergic system. However, the dysregulation of the 
monoamine system may continue. 
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ketamine are blocked by AMPA receptor antagonists, activation of AMPA receptors is 
presumably involved in the cellular mechanism of ketamine’s action (Maeng et al., 2008; 
Autry et al., 2011; Koike et al., 2011). These findings indicate that the rapid antidepressant 
response of ketamine is associated with the glutamatergic systems, including NMDA and 
AMPA receptors. 
Glutamate and GABA are the major excitatory and inhibitory neurotransmitters in the brain, 
respectively. The information processing of functional neural circuits is mediated by 
glutamate and GABA. All behaviors, including cognition and emotion, are performed by the 
glutamatergic/GABAergic neural circuits. The neurotransmitters of monoaminergic systems 
influence the activity of glutamate and GABA in these functional neural circuits (Fig. 2A). 
Thus, glutamate and GABA play a direct role in the expression of behaviors, while the 
monoaminergic systems, although not directly responsible, play a role in attenuating or 
strengthening it by modulating the activity of glutamatergic/GABAergic neural circuits. In 
depression, the degeneration of monoaminergic axons containing 5-HT and/or NA may 
occur, causing the influence of the monoaminergic systems on the functional neural circuits 
to continuously decline. Consequently, this may blunt the activity of functional neural 
circuits that process behaviors, including emotion (Fig. 2B), leading to depression and 
depressive states. Antidepressants affecting the activity of 5-HT and/or NA neurons induce 
the regeneration of previously degenerated monoaminergic axons and restore the normal 
conditions of functional neural circuits (Fig. 2C). The antidepressant effects of these 
antidepressants occur slowly due to the time required for morphological changes to take  
 
Fig. 2E. Administration of both fast- and slow-acting antidepressants may restore the 
normal conditions and operations of functional neural circuits within both the glutamatergic 
and monoaminergic systems. 
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place, and become manifest over several weeks. In contrast, fast-acting antidepressants such 
as ketamine, which affect the activity of the glutamatergic system, act directly on functional 
neural circuits to restore the normal healthy condition, while the monoamine systems 
remain dysregulated (Fig. 2D). To completely restore functionality of neural circuits, both 
the glutamatergic and monoaminergic systems must be restored to full capacity through 
administration of both fast- and slow-acting antidepressants (Fig. 2E). 
7. Concluding remarks 
The delayed onset of clinical efficacy of classical antidepressants may be explained, at least 
in part, by the fact that degeneration of 5-HT and/or NA axons is heavily involved in the 
pathophysiology of depression, and that such antidepressants exert their clinical efficacy by 
inducing a relatively slow regeneration of these monoaminergic axons. Although newer 
antidepressants that directly affect the glutamatergic system produce a rapid and sustained 
antidepressant response, the monoaminergic systems may remain suboptimal and in need 
of restoration. New antidepressant development should focus on maintaining these 
immediate effects of action on the glutamatergic system, but also restoring the modulatory 
activity of the monoaminergic systems in the long-term, possibly by inducing the 
regeneration of monoaminergic axons. 
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